Zhangyi Luo

The Modular CAR: Adapting T Cells without Reengineering Them

Abstract The therapeutic potential of chimeric antigen receptor (CAR) T cells has long been limited by the static nature of the engineered receptor; once manufactured, the cell is committed to a single antigen, unable to respond to the immune evasion and antigen heterogeneity tha...

Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy

Cancer immunotherapy has transformed cancer treatment, yet its efficacy remains limited by a “cold” tumor immune microenvironment (TIME) characterized by poor T cell infiltration. Induction of immunogenic cell death (ICD) improves T cell infiltration by promoting the release of T...